• Article  

      Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience 

      Waddell, T.; Kotsori, A.; Constantinidou, Anastasia; Yousaf, N.; Ashley, Sue; Parton, M.; Allen, M.; Starling, N.; Papadopoulos, P.; O'Brien, M.; Smith, I. E.; Johnston, S. L. (2011)
      BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ ve) advanced breast cancer. We have ...